Artemis Investment Management LLP Purchases 5,019,143 Shares of Pfizer Inc. $PFE

Artemis Investment Management LLP lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 849.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,609,880 shares of the biopharmaceutical company's stock after purchasing an additional 5,019,143 shares during the quarter. Pfizer comprises approximately 1.7% of Artemis Investment Management LLP's portfolio, making the stock its 12th largest holding. Artemis Investment Management LLP owned approximately 0.10% of Pfizer worth $139,686,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in PFE. Forza Wealth Management LLC boosted its holdings in shares of Pfizer by 21.2% during the fourth quarter. Forza Wealth Management LLC now owns 23,188 shares of the biopharmaceutical company's stock worth $577,000 after purchasing an additional 4,061 shares during the period. Cornerstone Planning Group LLC boosted its holdings in shares of Pfizer by 2,759.2% during the fourth quarter. Cornerstone Planning Group LLC now owns 4,346 shares of the biopharmaceutical company's stock worth $112,000 after purchasing an additional 4,194 shares during the period. Ping Capital Management Inc. boosted its holdings in shares of Pfizer by 66.7% during the fourth quarter. Ping Capital Management Inc. now owns 25,000 shares of the biopharmaceutical company's stock worth $622,000 after purchasing an additional 10,000 shares during the period. PFA Pension Forsikringsaktieselskab purchased a new stake in shares of Pfizer during the fourth quarter worth about $76,833,000. Finally, Manhattan West Asset Management LLC boosted its holdings in shares of Pfizer by 5.5% during the fourth quarter. Manhattan West Asset Management LLC now owns 91,216 shares of the biopharmaceutical company's stock worth $2,271,000 after purchasing an additional 4,726 shares during the period. Institutional investors own 68.36% of the company's stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA approval for a Pfizer–Arvinas breast cancer therapy — The U.S. FDA approved the co‑developed drug for a breast cancer indication, giving Pfizer an additional commercial launch and validating its oncology partnership pipeline. This approval creates a new near‑ and medium‑term revenue opportunity and reduces development risk for the asset. US FDA approves Pfizer, Arvinas' breast cancer drug
• Positive Sentiment: Vyndamax patent settlements extend exclusivity to 2031 — Pfizer reached settlements with multiple generic filers that effectively push back generic entry for Vyndamax (tafamidis), protecting a meaningful revenue stream and reducing downside risk from near‑term generic competition. That supports cash flow visibility into the next decade. Pfizer Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031
• Positive Sentiment: Late‑stage win for multiple myeloma drug Elrexfio — Pfizer reported a late‑stage trial success for Elrexfio, which could expand its oncology franchise and add future revenue streams if regulatory filings follow. Clinical wins can meaningfully re‑rate biotech exposure over time. Pfizer posts late-stage trial win for multiple myeloma therapy Elrexfio
• Positive Sentiment: PADCEV supplemental BLA accepted for priority review — Pfizer (with Astellas) secured FDA acceptance of a PADCEV sBLA for a new use, which could expand indications and sales if approved. This is another program that supports medium‑term growth optionality. Pfizer Among Best Medical Stocks Under $30 to Invest In?
• Neutral Sentiment: Q1 earnings and guidance in focus (May 5) — Wall Street is watching first‑quarter results and guidance; Zacks and other outlets highlight consensus estimates and key revenue/margin line items, with traders positioning ahead of potential beats and for commentary on obesity and specialty drug performance. Earnings will likely be the short‑term catalyst for direction. Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings
• Negative Sentiment: Analyst caution and price‑target cuts are weighing on sentiment — Goldman reportedly trimmed its target and some sell‑side commentary highlights growth concerns despite the patent wins; Morgan Stanley reiterated Equal Weight and flagged patent/growth uncertainty. That cautious analyst tone can sap momentum and contribute to intraday selling. Pfizer Stock Opinions on Vyndamax Settlements and Earnings Outlook Morgan Stanley Maintains Pfizer at Equal Weight

Analyst Ratings Changes

A number of analysts have recently weighed in on PFE shares. Royal Bank Of Canada reiterated an "underperform" rating and set a $25.00 target price on shares of Pfizer in a report on Monday, April 20th. Zacks Research upgraded shares of Pfizer from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 24th. Barclays started coverage on shares of Pfizer in a report on Thursday, February 19th. They set an "underweight" rating and a $25.00 target price for the company. Argus upgraded shares of Pfizer from a "hold" rating to a "buy" rating and set a $35.00 target price for the company in a report on Monday, March 2nd. Finally, Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of "Hold" and an average price target of $28.74.

Pfizer Trading Down 1.3%

Shares of PFE stock opened at $26.35 on Friday. Pfizer Inc. has a 12-month low of $21.97 and a 12-month high of $28.75. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The firm's 50 day moving average is $27.17 and its 200 day moving average is $26.09. The stock has a market capitalization of $149.80 billion, a P/E ratio of 19.37 and a beta of 0.35.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analysts' expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company's revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.63 EPS. Research analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. The ex-dividend date is Friday, May 8th. Pfizer's dividend payout ratio (DPR) is currently 126.47%.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.